Sophia genetics
Precision oncology
Sophia genetics, a leader in AI-driven precision medicine has announced two collaborations. Firstly with Element Biosciences, a company that works to innovate the core components of sequencing to introduce a radically new way of generating genomics data while reducing run costs and improving performance. Secondly, with Complete Genomics, a fellow sequencing pioneer. The partnership with Element Biosciences will unite sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine. The partnership with Complete Genomics will broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumour applications to customers globally.
Biodesix
Mutation detection assay
Biodesix has announced the signing of an expanded partnership agreement under which it will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilising Bio-Rad’s Droplet Digital PCR technology on Bio-Rad’s QX600 platform. Following regulatory clearance, Biodesix will manufacture and distribute dedicated specimen collection kits for the developed assays.
Post comments